PDF) A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic haematopoietic cell transplant recipients
A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic haematopoietic cell transplant recipients - eClinicalMedicine
Pharmacokinetics and Immunogenicity of ASP0113 in CMV‐Seronegative Dialysis Patients and CMV‐Seronegative and ‐Seropositive Healthy Subjects - Bonate - 2020 - Clinical Pharmacology in Drug Development - Wiley Online Library
Kidney Transplant | Dr. Piotr Witkowski | UChicago
A new era in cytomegalovirus vaccinology: considerations for rational design of next-generation vaccines to prevent congenital cytomegalovirus infection | npj Vaccines
Another Vical vax flop, this time with Astellas-partnered CMV vaccine | Fierce Biotech
Herpes Vaccine Candidate Fails in Clinical Trial — Precision Vaccinations
Vaccine therapy for cytomegalovirus in the setting of allogeneic hematopoietic cell transplantation: Expert Review of Vaccines: Vol 14, No 3
Astellas Pharma US | Results for Cytomegalovirus Vaccine ASP0113 Trial
Clinical development timeline of ASP0113 (TransVax) from product... | Download Scientific Diagram
Astellas and Vical Announce Top-Line Results for Phase 3
Clinical Trials
Vaccines | Free Full-Text | Comparison of Current Regulatory Status for Gene-Based Vaccines in the U.S., Europe and Japan | HTML
Vaccines | Free Full-Text | Development of a Vaccine against Human Cytomegalovirus: Advances, Barriers, and Implications for the Clinical Practice | HTML
Clinical development timeline of ASP0113 (TransVax) from product... | Download Scientific Diagram
A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic haematopoietic cell transplant recipients - eClinicalMedicine
A randomized, phase 2 study of ASP0113, a DNA‐based vaccine, for the prevention of CMV in CMV‐seronegative kidney transplant recipients receiving a kidney from a CMV‐seropositive donor - Vincenti - 2018 -
Pursuing Victory: Moderna Begins Dosing in Phase III CMV Trial
Status of HCMV vaccines and antibody-based therapeutics with clinical data. | Download Table
A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic haematopoietic cell transplant recipients - eClinicalMedicine
Vical's Astellas-partnered CMV vaccine falls short again, this time in stem cell transplant recipients | Fierce Pharma
Astellas' cytomegalovirus vaccine fails to meet Phase III endpoints - Clinical Trials Arena
Clinical development timeline of ASP0113 (TransVax) from product... | Download Scientific Diagram
Choice of Study Populations for Vaccines | The Journal of Infectious Diseases | Oxford Academic
A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic haematopoietic cell transplant recipients - eClinicalMedicine
